Zacks: Analysts Anticipate Allakos Inc (NASDAQ:ALLK) to Post -$0.45 Earnings Per Share

Wall Street analysts expect that Allakos Inc (NASDAQ:ALLK) will announce earnings of ($0.45) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Allakos’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.41). Allakos posted earnings per share of ($0.34) during the same quarter last year, which would indicate a negative year over year growth rate of 32.4%. The business is scheduled to report its next earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Allakos will report full-year earnings of ($1.83) per share for the current financial year, with EPS estimates ranging from ($1.91) to ($1.74). For the next financial year, analysts expect that the firm will post earnings of ($2.44) per share, with EPS estimates ranging from ($2.58) to ($2.30). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Allakos.

Allakos (NASDAQ:ALLK) last posted its earnings results on Monday, August 5th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.03.

A number of research analysts recently weighed in on ALLK shares. William Blair reissued a “buy” rating on shares of Allakos in a report on Friday, August 9th. Zacks Investment Research lowered shares of Allakos from a “buy” rating to a “hold” rating in a report on Friday, August 16th.

Shares of ALLK stock traded up $1.01 on Thursday, reaching $79.64. The company’s stock had a trading volume of 501,242 shares, compared to its average volume of 461,465. The stock’s fifty day simple moving average is $85.07 and its 200-day simple moving average is $52.19. Allakos has a 1 year low of $29.34 and a 1 year high of $92.84. The company has a market capitalization of $3.41 billion, a price-to-earnings ratio of -36.20 and a beta of -1.31.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of Montreal Can purchased a new position in Allakos during the second quarter worth $63,000. BNP Paribas Arbitrage SA boosted its stake in Allakos by 4,853.8% during the first quarter. BNP Paribas Arbitrage SA now owns 3,220 shares of the company’s stock worth $130,000 after buying an additional 3,155 shares during the period. Amundi Pioneer Asset Management Inc. purchased a new position in Allakos during the first quarter worth $142,000. SG Americas Securities LLC purchased a new position in Allakos during the first quarter worth $153,000. Finally, Bank of America Corp DE boosted its stake in Allakos by 264.0% during the fourth quarter. Bank of America Corp DE now owns 4,153 shares of the company’s stock worth $217,000 after buying an additional 3,012 shares during the period. 58.38% of the stock is owned by institutional investors.

About Allakos

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

See Also: What is a stock portfolio tracker?

Get a free copy of the Zacks research report on Allakos (ALLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allakos (NASDAQ:ALLK)

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.